ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically targeted therapies for heart failure and other
cardiovascular diseases, today announced that it has received a Notice
of Allowance from the U.S. Patent and Trademark Office (USPTO) for its
U.S. Patent Application Number 11/226,908 entitled “Methods for
Treatment with Bucindolol Based on Genetic Targeting.” The Notice of
Allowance is the USPTO’s official communication that the examination of
the patent application has been successfully completed and that a patent
will be issued. Once issued, the patent will provide coverage for
methods of treating heart failure patients with bucindolol based on
genetic testing.
“This allowance and anticipated
issuance of the patent highlight ARCA’s belief in, and commitment to,
developing genetically targeted therapies for the treatment of heart
failure and other cardiovascular diseases.”
“We are very pleased with the USPTO’s decision to grant this patent
which extends our pharmacogenetic intellectual property protection
around bucindolol in to 2025,” said Michael R. Bristow, President and
Chief Executive Officer of ARCA. “This allowance and anticipated
issuance of the patent highlight ARCA’s belief in, and commitment to,
developing genetically targeted therapies for the treatment of heart
failure and other cardiovascular diseases."
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis